Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Author: Benzinga Newsdesk | January 18, 2024 07:56am

United States Court Of Appeals For The Federal Circuit Affirmed The Previously Announced Decision By The United States District Court For The District Of Delaware Finding That Drug Applications Referencing Eagle Pharmaceuticals' Belrapzo (Bendamustine) Filed By Slayback Pharma And Apotex Did Not Infringe Eagle's Previously Issued ‘483 Patent

Posted In: EGRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist